openPR Logo
Press release

Scleroderma Pipeline Analysis, Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies | Biocad, Certa Therapeutics, Emerald Health, Acceleron, Kyowa Kirin, Bayer, Boehringer Ingelheim, Maruho, Prometheus Biosciences

08-21-2023 06:01 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Scleroderma Pipeline Analysis, Clinical and Non-Clinical

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 45+ key pharma and biotech companies are working on 50+ pipeline drugs in the Scleroderma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Scleroderma Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Scleroderma Therapeutics Market.

The report provides a detailed description of the Scleroderma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Scleroderma Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Scleroderma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Scleroderma therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Scleroderma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Scleroderma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Scleroderma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Scleroderma Therapeutics Domain:
https://www.delveinsight.com/report-store/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Scleroderma Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Scleroderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Mechanism of Action of the Emerging Therapies
• Antibody-dependent cell cytotoxicity
• Lysophosphatidic acid receptor antagonists
• Soluble guanylyl cyclase agonists
• Tubulin polymerisation inhibitor
• Transforming growth factor beta inhibitor
• Serotonin 2B receptor antagonists

Request for Sample PDF to Understand More About the Scleroderma Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Scleroderma Therapeutics Analysis
There are approx. 45+ key companies developing therapies for Scleroderma. Currently, Certa Therapeutics is leading the therapeutics market with its Scleroderma drug candidates in the most advanced stage of clinical development.

Scleroderma Companies in the Therapeutics Market Include:
• Biocad
• Certa Therapeutics
• Emerald Health Pharmaceuticals
• Acceleron Pharma
• Kyowa Kirin
• Bayer
• Boehringer Ingelheim
• Maruho Co., Ltd.
• Mitsubishi Tanabe Pharma
• Prometheus Biosciences
And Many Others

Emerging and Marketed Scleroderma Therapies Covered in the Report Include:
• FT011: Certa Therapeutics
• EHP 101: Emerald Health Pharmaceuticals
• ACE-1334: Acceleron Pharma
And Many More

Get an in-depth Assessment of the Emerging Therapies and Scleroderma Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Scleroderma Current Treatment Patterns
4. Scleroderma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Scleroderma Late-Stage Products (Phase-III)
7. Scleroderma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Scleroderma Discontinued Products
13. Scleroderma Product Profiles
14. Scleroderma Companies
15. Scleroderma Drugs
16. Dormant and Discontinued Products
17. Scleroderma Unmet Needs
18. Scleroderma Future Perspectives
19. Scleroderma Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Aneurysmal Subarachnoid Hemorrhage (SAH) Market
https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market

Dupuytren's Disease Market
https://www.delveinsight.com/report-store/dupuytrens-disease-market

Homocystinuria Market
https://www.delveinsight.com/report-store/homocystinuria-market-new

Platinum-Resistant Relapsed Ovarian Cancer Market
https://www.delveinsight.com/report-store/platinum-resistant-relapsed-ovarian-cancer-market

Dementia with Diabetes Market
https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast

Pyruvate Kinase Deficiency Market
https://www.delveinsight.com/report-store/pyruvate-kinase-deficiency-market

Uterine Serous Carcinoma Market
https://www.delveinsight.com/report-store/uterine-serous-carcinoma-market

Paraganglioma Market
https://www.delveinsight.com/report-store/paraganglioma-market

Spinal Cord Stimulators (SCS) Global Market
https://www.delveinsight.com/report-store/spinal-cord-stimulator-market

Adult Spinal Deformity Market
https://www.delveinsight.com/report-store/adult-spinal-deformity-market

Age-related Vision Dysfunction Market
https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market

Erythropoietic Protoporphyria Market
https://www.delveinsight.com/report-store/erythropoietic-protoporphyria-market

Juvenile Idiopathic arthritis (JIA) Market
https://www.delveinsight.com/report-store/juvenile-idiopathic-arthritis-jia-market

Otoscope Market
https://www.delveinsight.com/report-store/otoscope-market

Surgical Energy Generators Market
https://www.delveinsight.com/report-store/surgical-energy-generators-market

Eosinophilic Esophagitis Market
https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market

Hypereosinophilic Syndrome Market
https://www.delveinsight.com/report-store/hypereosinophilic-syndrome-market

Campylobacter Infections Market
https://www.delveinsight.com/report-store/campylobacter-infections-market

Degenerative Disc Disease Market
https://www.delveinsight.com/report-store/degenerative-disc-disease-ddd-market

Optic Neuritis Market
https://www.delveinsight.com/report-store/optic-neuritis-market

Shoulder Replacement Devices Global Market
https://www.delveinsight.com/report-store/shoulder-replacement-devices-market

Scleritis Market
https://www.delveinsight.com/report-store/scleritis-market

Polypoidal Choroidal Vasculopathy (PCV) Market
https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market

Post-Polycythemia Vera Myelofibrosis Market
https://www.delveinsight.com/report-store/post-polycythemia-vera-myelofibrosis-market

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Market
https://www.delveinsight.com/report-store/severe-acute-respiratory-syndrome-sars-coronavirus-infection-market

Cardiac Biomarkers Testing Devices Global Market
https://www.delveinsight.com/report-store/cardiac-biomarkers-testing-devices-market

Graves Orbitopathy Market
https://www.delveinsight.com/report-store/graves-orbitopathy-market

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market
https://www.delveinsight.com/report-store/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Febrile Neutropenia Market
https://www.delveinsight.com/report-store/febrile-neutropenia-market

Axial Spondyloarthritis Market
https://www.delveinsight.com/report-store/axial-spondyloarthritis-market

Conductive Hearing Loss Market
https://www.delveinsight.com/report-store/conductive-hearing-loss-market

Metastatic Cutaneous Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/metastatic-cutaneous-squamous-cell-carcinoma-market

Ocular Melanoma Market
https://www.delveinsight.com/report-store/ocular-melanoma-market

Schistosomiasis Market
https://www.delveinsight.com/report-store/schistosomiasis-market

Adenosine Deaminase-Severe Combined Immunodeficiency Market
https://www.delveinsight.com/report-store/adenosine-deaminase-severe-combined-immunodeficiency-market

Dermal Erythema Market
https://www.delveinsight.com/report-store/dermal-erythema-market

Hypercalcemia Market
https://www.delveinsight.com/report-store/hypercalcemia-market

Marginal Zone Lymphoma Market
https://www.delveinsight.com/report-store/marginal-zone-lymphoma-market

Tonsillitis Market
https://www.delveinsight.com/report-store/tonsillitis-marke

Biliary Atresia Market
https://www.delveinsight.com/report-store/biliary-atresia-market

Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market

Retinoblastoma Market
https://www.delveinsight.com/report-store/retinoblastoma-market

Dysautonomia (Autonomic Dysfunction) Market
https://www.delveinsight.com/report-store/dysautonomia-autonomic-dysfunction-market

IgA Nephropathy (IgAN) Market
https://www.delveinsight.com/report-store/iga-nephropathy-market

Kyphoscoliosis Market
https://www.delveinsight.com/report-store/kyphoscoliosis-market

Myofascial Pain Syndrome Market
https://www.delveinsight.com/report-store/myofascial-pain-syndrome-market

Osteogenesis Imperfecta Market
https://www.delveinsight.com/report-store/osteogenesis-imperfecta-oi-market

Treatment-Resistant Depression (TRD) Market
https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market

Fallopian Tube Cancer Market
https://www.delveinsight.com/report-store/fallopian-tube-cancer-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Scleroderma Pipeline Analysis, Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies | Biocad, Certa Therapeutics, Emerald Health, Acceleron, Kyowa Kirin, Bayer, Boehringer Ingelheim, Maruho, Prometheus Biosciences here

News-ID: 3173671 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Scleroderma

Key Factor Supporting Scleroderma Market Development in 2025: Rising Scleroderma …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Scleroderma Market Size By 2025? The market size of scleroderma has notably expanded in past years. It is projected to rise from a value of $2.33 billion in 2024 up to $2.49 billion in 2025, posting a compound annual growth rate (CAGR) of 6.9%. The
Scleroderma Market Trends, Size, Share And Analysis 2024-2033
"The new report published by The Business Research Company, titled Scleroderma Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. As per the report, the scleroderma market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to
Scleroderma Therapeutics Market, By Indication (Localized Scleroderma, Systemic …
Scleroderma therapeutics market size is projected to grow at a compound annual growth rate of 5.7% over the forecast period of 2021 to 2028. Data Bridge Market Research report on scleroderma therapeutics market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market's growth. View Detailed Report: https://www.databridgemarketresearch.com/reports/global-scleroderma-therapeutics-market Scleroderma is a rare auto-immune disease which is generally characterized by
Scleroderma Therapeutics Market, By Indication (Localized Scleroderma, Systemic …
Scleroderma therapeutics market size is projected to grow at a compound annual growth rate of 5.7% over the forecast period of 2021 to 2028. Data Bridge Market Research report on scleroderma therapeutics market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market's growth. View Detailed Report: https://www.databridgemarketresearch.com/reports/global-scleroderma-therapeutics-market Scleroderma is a rare auto-immune disease which is generally characterized by
Scleroderma Pipeline | 20+ Key Players & 22+ Pipeline Drugs | DelveInsight
DelveInsight's, "Scleroderma Pipeline Insight, 2022," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Scleroderma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key takeaways from the Scleroderma Pipeline Insight Report • DelveInsight's analysis depicts a robust
Scleroderma Therapeutics Market Analysis - Forecast to 2026
As per the research conducted by GME, the Global Scleroderma Therapeutics Market will grow with a CAGR value of 6.1 percent. Moreover, the rising R&D activities along with the advancing technology and increasing government spending in the pharma industry has boosted the market and growth will be seen in the future. Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Scleroderma Therapeutics Market